Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Operating Expenses: 2011-2024

Historic Other Operating Expenses for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $4.6 million.

  • Adma Biologics' Other Operating Expenses rose 24.88% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 21.51%. This contributed to the annual value of $4.6 million for FY2024, which is 7.15% down from last year.
  • Adma Biologics' Other Operating Expenses amounted to $4.6 million in FY2024, which was down 7.15% from $5.0 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Other Operating Expenses ranged from a high of $18.6 million in FY2022 and a low of $4.6 million during FY2024.
  • Moreover, its 3-year median value for Other Operating Expenses was $5.0 million (2023), whereas its average is $9.4 million.
  • As far as peak fluctuations go, Adma Biologics' Other Operating Expenses skyrocketed by 166.18% in 2021, and later slumped by 73.11% in 2023.
  • Adma Biologics' Other Operating Expenses (Yearly) stood at $4.9 million in 2020, then soared by 166.18% to $13.0 million in 2021, then skyrocketed by 42.71% to $18.6 million in 2022, then slumped by 73.11% to $5.0 million in 2023, then dropped by 7.15% to $4.6 million in 2024.